Dr. Ramien explores the concept of disease modification in AD focusing on disease control, and the prevention or slowing of development of atopic comorbidities.
The Journey of Diagnosis: Disease Burden and Diagnostic Considerations for Atopic Dermatitis and Prurigo Nodularis
Dermatology
In this ADVENT symposium at the 2024 Diversity in Dermatology conference, Dr(s) Sarina Elmariah and Mona Shahriari engage in a dynamic discussion on diagnostic considerations and challenges associated with atopic dermatitis and prurigo nodularis.
Type 2 Inflammation and Its Role in Associated Dermatologic Diseases: A Two-Part Series
Type 2 Inflammation
Join Dr. Raj Chovatiya as he reviews the pathophysiology and the role of type 2 inflammation in atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.